Three people were able to suppress the virus for months without their usual treatment regimen.

On the occasion of World AIDS Day on 1 December 2024, the International Antiviral (formerly AIDS) Society-USA (IAS-USA) has published new international guidelines for the treatment and prevention of ...

– Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – “Striving for continuous progress in HIV means delivering ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

The COVID-19 pandemic paused many HIV prevention efforts, which helped fuel last year's rise in new infections. President Donald Trump's federal funding cuts threaten to further hamper those efforts.

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted Gilead Sciences’ new drug application for a single-tablet, once-daily HIV treatment ...

On Thursday, the FDA signed off on Genvoya, a new complete treatment regimen for HIV-1 infection in adults and pediatric patients 12 years or older. Genyova is a fixed-dose combination tablet ...

Here are three things to know. 1. Trogarzo is an antiretroviral medication for adult patients with HIV who do not respond to other HIV therapies on the market. 2. Clinicians administer the intravenous ...

Gilead Sciences, Inc. today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd ...